single5MG
MOTS-C
5MG Protocol
MOTS-C 5MG
Injection Freq.
Inject once daily
Cycle Sched.
4–8 weeks on, followed by 4–8 weeks off; avoid continuous long‑term use without breaks
Reconstitution
3.0 mL BAC water
Improved insulin sensitivity and glucose metabolism in preclinical models
Increased fat oxidation
reduced diet-induced obesity/insulin resistance in animals
Improved exercise capacity and muscle homeostasis signals in aging models
No IGF-1 stimulation or adverse glucose-tolerance effects described versus GH-axis agents
Generally well tolerated in animal studies at typical doses (as described)
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 500 mcg (0.5 mg) | 30 |
| 2 | Weeks 3–4 | 1000 mcg (1.0 mg) | 60 |
| 3 | Weeks 5–6 | 1500 mcg (1.5 mg) | 90 |
| 4 | Weeks 7–8 | 2000 mcg (2.0 mg) | 120 |
Inject once daily
4–8 weeks on, followed by 4–8 weeks off; avoid continuous long‑term use without breaks
MOTS-C is described as a mitochondria-derived peptide that acts as a metabolic ‘stress signal’ and shifts cells toward an energy-efficient, exercise-like state. In the protocol, its central pathway is AMPK activation: MOTS-C is described as enhancing glucose uptake, increasing fat oxidation, and reducing lipid accumulation in muscle and adipose tissue. The page contrasts its tissue focus with metformin by highlighting direct skeletal-muscle and fat-tissue effects in preclinical models. Under metabolic stress, MOTS-C is also described as translocating to the nucleus, where it can influence nuclear gene expression as a form of mitochondria-to-nucleus retrograde signaling. The protocol notes that endogenous MOTS-C rises markedly with exercise and declines with aging, which is presented as rationale for interest in age-related metabolic decline, insulin resistance, and obesity research. A key limitation emphasized is the absence of completed formal human clinical trials; therefore, the described mechanism and outcomes are largely grounded in animal and cellular studies.
Mild injection-site reactions (redness/bruising/inflammation) reported anecdotally
Long-term human safety data not available
chronic continuous use beyond ~8 weeks uncharacterized
Theoretical receptor/pathway downregulation with prolonged daily use (cycling recommended)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)